2023
Surveillance of Individuals at High Risk of Developing Pancreatic Cancer
Paiella S, Secchettin E, Lionetto G, Archibugi L, Azzolina D, Casciani F, Simeone D, Overbeek K, Goggins M, Farrell J, de Leon Pisani R, Tridenti M, Corciulo M, Malleo G, Arcidiacono P, Falconi M, Gregori D, Bassi C, Salvia R, Capurso G. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer. Annals Of Surgery 2023, 279: 37-44. PMID: 37681303, DOI: 10.1097/sla.0000000000006094.Peer-Reviewed Original ResearchConceptsPancreatic cancer surveillanceHigh-risk individualsCancer surveillancePancreatic cancerPooled prevalenceFinal diagnosisPancreatic cancer subjectsLow-grade dysplasiaDysplastic precursor lesionsNon-neoplastic conditionsPathogenic variant carriersPancreatic resectionSecondary outcomesPooled proportionSubgroup analysisTarget lesionsPrecursor lesionsSurveillance of individualsCancer subjectsVariant carriersEffect modifiersHigh riskHereditary predispositionSurgeryPathogenic variants
2022
Density patterns of tumor-infiltrating lymphocytes and association with objective response to nivolumab in patients with lung adenocarcinoma from CheckMate 057.
Corredor G, Ding R, Prasanna P, Barrera C, Toro P, Viswanathan V, Zens P, Berezowska S, Baxi V, Balli D, Belete M, Velcheti V, Schalper K, Madabhushi A. Density patterns of tumor-infiltrating lymphocytes and association with objective response to nivolumab in patients with lung adenocarcinoma from CheckMate 057. Journal Of Clinical Oncology 2022, 40: 2662-2662. DOI: 10.1200/jco.2022.40.16_suppl.2662.Peer-Reviewed Original ResearchTumor-infiltrating lymphocytesImmune checkpoint inhibitorsOverall survivalLung adenocarcinomaCheckMate 057Objective responseRisk scoreAnalysis of TILAdvanced-stage lung adenocarcinomaPlatinum-based chemotherapyRisk of progressionCox regression modelDeath risk scoreStage lung adenocarcinomaLung cancer subjectsRECIST v1.1Checkpoint inhibitorsHazard ratioTIL densityPD-L1Better prognosisTumor responseClinical trialsCancer subjectsNivolumab
2019
Hybrid Neural Networks for Mortality Prediction from LDCT Images
Yan P, Guo H, Wang G, De Man R, Kalra MK. Hybrid Neural Networks for Mortality Prediction from LDCT Images. Annual International Conference Of The IEEE Engineering In Medicine And Biology Society (EMBC) 2019, 00: 6243-6246. PMID: 31947269, DOI: 10.1109/embc.2019.8857180.Peer-Reviewed Original ResearchConceptsLow-dose CTMortality predictionLung cancer patientsCancer mortality predictionsMortality risk predictionLung cancer subjectsCause mortalityHigh morbidityCancer patientsLung cancerImaging featuresCardiovascular diseaseCancer subjectsHigh riskMortality riskRisk scoreMortality rateClinical practiceDeadly diseaseRisk predictionLDCT imagesDiseaseRiskSame populationScoring method
2015
Hypothermia for preventing chemotherapy-induced neuropathy – a pilot study on safety and tolerability in healthy controls
Bandla A, Sundar R, Liao L, Tan S, Lee S, Thakor N, Wilder-Smith E. Hypothermia for preventing chemotherapy-induced neuropathy – a pilot study on safety and tolerability in healthy controls. Acta Oncologica 2015, 55: 430-436. PMID: 26360921, DOI: 10.3109/0284186x.2015.1075664.Peer-Reviewed Original ResearchConceptsChemotherapy-induced peripheral neuropathyHealthy human subjectsHealthy subjectsSevere chemotherapy-induced peripheral neuropathyDose-limiting side effectReduced nerve blood flowSeverity of chemotherapy-induced peripheral neuropathyLimb hypothermiaAdjuvant weekly paclitaxelChemotherapy-induced neuropathyNerve blood flowDuration of chemotherapyBreast cancer patientsSuccess of chemotherapyInfluence of hypothermiaEffects of hypothermiaWeekly paclitaxelSignificant adverse effectsPaclitaxel chemotherapyTreatment discontinuationTransient numbnessDose-relatedNeurotoxic drugsHuman subjectsCancer subjects
2004
A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease
Cameron D, Winer E, Campos S, Guastalla J. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. Journal Of Clinical Oncology 2004, 22: 628-628. DOI: 10.1200/jco.2004.22.14_suppl.628.Peer-Reviewed Original ResearchA comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease
Cameron D, Winer E, Campos S, Guastalla J. A comparative study of exemestane versus anastrozole in post-menopausal breast cancer subjects with visceral disease. Journal Of Clinical Oncology 2004, 22: 628-628. DOI: 10.1200/jco.2004.22.90140.628.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply